Idiopathic thrombocytopenic purpura pathophysiology: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 17: Line 17:
* '''Increased platelet destruction:'''
* '''Increased platelet destruction:'''
** '''Autoantibody‐induced platelet destruction'''
** '''Autoantibody‐induced platelet destruction'''
*** Abnormal IgG auto-antibody recognizes glyco-protein IIb/IIIa, glyco-protein Ib/IX complex, GP Ia/IIa, and GP VI etc
*** Abnormal IgG auto-antibody recognizes glyco-protein IIb/IIIa, glyco-protein Ib/IX complex, GP Ia/IIa, and GP VI etc<ref name="pmid15720967">{{cite journal |vauthors=McMillan R |title=The role of antiplatelet autoantibody assays in the diagnosis of immune thrombocytopenic purpura |journal=Curr. Hematol. Rep. |volume=4 |issue=2 |pages=160–5 |date=March 2005 |pmid=15720967 |doi= |url=}}</ref>
*** Majority of these auto-antibodies are IgG, but IgM and IgA can also be identified in some patients with AITP
*** Majority of these auto-antibodies are IgG, but IgM and IgA can also be identified in some patients with AITP
*** Predominantly IgG auto-antibodies constitute the majority of antibodies but IgM and IgA antibodies can also be found in some of ITP patients.
*** Predominantly IgG auto-antibodies constitute the majority of antibodies but IgM and IgA antibodies can also be found in some of ITP patients.
*** Auto-antibodies binds to the circulating platelet membranes through glyco-proteins
*** Auto-antibodies binds to the circulating platelet membranes through glyco-proteins
*** Auto-antibody-coated platelets induce Fcg receptors and bind to antigen-presenting cells (Splenic macrophages or dendritic cells) in the reticulo-endothelial system
*** Auto-antibody-coated platelets induce Fcγ receptors and bind to antigen-presenting cells (Splenic macrophages or dendritic cells) in the reticulo-endothelial system<ref name="pmid5214832">{{cite journal |vauthors=Shulman NR, Marder VJ, Weinrach RS |title=Similarities between known antiplatelet antibodies and the factor responsible for thrombocytopenia in idiopathic purpura. Physiologic, serologic and isotopic studies |journal=Ann. N. Y. Acad. Sci. |volume=124 |issue=2 |pages=499–542 |date=June 1965 |pmid=5214832 |doi= |url=}}</ref>
*** The auto-antibody-coated platelets undergo phagocytosis by splenic macrophages and peripheral blood neutrophils.
*** The auto-antibody-coated platelets undergo phagocytosis by splenic macrophages and peripheral blood neutrophils.
** '''Autoreactive T lymphocyte‐mediated platelet lysis'''
** '''Autoreactive T lymphocyte‐mediated platelet lysis'''
*** Abnormal cytotoxic T cells defect leads to differentiation of direct autoreactive B cells further leading to secretion of IgG auto-antibodies.
*** Abnormal cytotoxic T cells defect leads to differentiation of direct autoreactive B cells further leading to secretion of IgG auto-antibodies<ref name="pmid12937414">{{cite journal |vauthors=Olsson B, Andersson PO, Jernås M, Jacobsson S, Carlsson B, Carlsson LM, Wadenvik H |title=T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura |journal=Nat. Med. |volume=9 |issue=9 |pages=1123–4 |date=September 2003 |pmid=12937414 |doi=10.1038/nm921 |url=}}</ref>
*** Abnormal T cells includes cytotoxic T-lymphocyte (CD8+) and natural killer cells (CD3- CD16+ CD56+)<ref name="pmid16480433">{{cite journal |vauthors=Zhang F, Chu X, Wang L, Zhu Y, Li L, Ma D, Peng J, Hou M |title=Cell-mediated lysis of autologous platelets in chronic idiopathic thrombocytopenic purpura |journal=Eur. J. Haematol. |volume=76 |issue=5 |pages=427–31 |date=May 2006 |pmid=16480433 |doi=10.1111/j.1600-0609.2005.00622.x |url=}}</ref>
*** CD4-positive helper T cells react with platelet surface glycoproteins, through co-stimulation involving CD40:CD40L
*** CD4-positive helper T cells react with platelet surface glycoproteins, through co-stimulation involving CD40:CD40L
*** T cells act directly on the megakaryocytes in the bone marrow
*** T cells act directly on the megakaryocytes in the bone marrow

Revision as of 18:17, 2 November 2018

Idiopathic thrombocytopenic purpura Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Idiopathic thrombocytopenic purpura from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Radiation

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Idiopathic thrombocytopenic purpura pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Idiopathic thrombocytopenic purpura pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Idiopathic thrombocytopenic purpura pathophysiology

CDC on Idiopathic thrombocytopenic purpura pathophysiology

Idiopathic thrombocytopenic purpura pathophysiology in the news

Blogs on Idiopathic thrombocytopenic purpura pathophysiology

Directions to Hospitals Treating Idiopathic thrombocytopenic purpura

Risk calculators and risk factors for Idiopathic thrombocytopenic purpura pathophysiology

increased platelet destructionEditor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Auto-immune thrombocytopenic purpura is described by the increased platelet destruction due to production of auto-reactive antibodies against host platelets and suppression of platelet production in the bone marrow.

Pathophysiology

Pathogenesis

Acute ITP: Mainly affects children and usually follows a viral or bacterial infection

  • Antigenic mimicry - Similar molecular structures on both host cells and infectious agents, inducing a self immune response which cross reacts with the host antigens.
    • In acute ITP - anti-viral or anti-bacterial antibodies cross reacts against the patient's platelets.
  • Mostly acute ITP is self resolving as infectious agents and antibodies are cleared from the body, causing the loss of anti-platelet reactivity.
  • T cells are not involved in the parthenogenesis of acute ITP

Chronic ITP: (platelet counts < 150,000 x 109 per liter x 6 months) usually in adults

  • Increased platelet destruction:
    • Autoantibody‐induced platelet destruction
      • Abnormal IgG auto-antibody recognizes glyco-protein IIb/IIIa, glyco-protein Ib/IX complex, GP Ia/IIa, and GP VI etc[1]
      • Majority of these auto-antibodies are IgG, but IgM and IgA can also be identified in some patients with AITP
      • Predominantly IgG auto-antibodies constitute the majority of antibodies but IgM and IgA antibodies can also be found in some of ITP patients.
      • Auto-antibodies binds to the circulating platelet membranes through glyco-proteins
      • Auto-antibody-coated platelets induce Fcγ receptors and bind to antigen-presenting cells (Splenic macrophages or dendritic cells) in the reticulo-endothelial system[2]
      • The auto-antibody-coated platelets undergo phagocytosis by splenic macrophages and peripheral blood neutrophils.
    • Autoreactive T lymphocyte‐mediated platelet lysis
      • Abnormal cytotoxic T cells defect leads to differentiation of direct autoreactive B cells further leading to secretion of IgG auto-antibodies[3]
      • Abnormal T cells includes cytotoxic T-lymphocyte (CD8+) and natural killer cells (CD3- CD16+ CD56+)[4]
      • CD4-positive helper T cells react with platelet surface glycoproteins, through co-stimulation involving CD40:CD40L
      • T cells act directly on the megakaryocytes in the bone marrow
  • Autoantibody‐mediated suppression of platelet production:
    • Decreased platelet turnover[5]
    • Abnormal thrombopoiesis
    • Autoantibody‐induced suppression of megakaryocytopoiesis
    • Megakaryocitic nuclei and cytoplasm shows degenrative changes

Genetics

Associated Conditions

Conditions associated with

Gross Pathology

On gross pathology, characteristic findings of itp include:

  • Acute
  • Chronic

Microscopic Pathology

On microscopic histopathological analysis, characteristic findings of itp include:

  • Acute
  • Chronic

References

Template:WH Template:WS


References

  1. McMillan R (March 2005). "The role of antiplatelet autoantibody assays in the diagnosis of immune thrombocytopenic purpura". Curr. Hematol. Rep. 4 (2): 160–5. PMID 15720967.
  2. Shulman NR, Marder VJ, Weinrach RS (June 1965). "Similarities between known antiplatelet antibodies and the factor responsible for thrombocytopenia in idiopathic purpura. Physiologic, serologic and isotopic studies". Ann. N. Y. Acad. Sci. 124 (2): 499–542. PMID 5214832.
  3. Olsson B, Andersson PO, Jernås M, Jacobsson S, Carlsson B, Carlsson LM, Wadenvik H (September 2003). "T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura". Nat. Med. 9 (9): 1123–4. doi:10.1038/nm921. PMID 12937414.
  4. Zhang F, Chu X, Wang L, Zhu Y, Li L, Ma D, Peng J, Hou M (May 2006). "Cell-mediated lysis of autologous platelets in chronic idiopathic thrombocytopenic purpura". Eur. J. Haematol. 76 (5): 427–31. doi:10.1111/j.1600-0609.2005.00622.x. PMID 16480433.
  5. Ballem PJ, Segal GM, Stratton JR, Gernsheimer T, Adamson JW, Slichter SJ (July 1987). "Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance". J. Clin. Invest. 80 (1): 33–40. doi:10.1172/JCI113060. PMC 442198. PMID 3597777.

Template:WH Template:WS